/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Caribou Biosciences

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.87 0.0568(5.68%) CRBU at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 1.76
Highest Today 1.865
Today’s Open 1.77
Prev. Close 1.76
52 Week High 3.54
52 Week Low 0.66
Day’s Range: Low 1.76 High 1.865
52-Week Range: Low 0.66 High 3.54
1 day return -
1 Week return -4.11
1 month return -13.65
3 month return +1.08
6 month return +64.31
1 year return -8.35
3 year return -79.57
5 year return -
10 year return -

Institutional Holdings

Pfizer Inc 5.04

Vanguard Group Inc 4.39

Kynam Capital Management, LP 3.29

Vanguard Total Stock Mkt Idx Inv 2.84

Schonfeld Strategic Advisors LLC 2.44

ACATIS Datini Valueflex Fonds A 2.15

BlackRock Inc 2.02

Millennium Management LLC 1.67

Selectra J. Lamarck Biotech A 1.61

Two Sigma Advisers, LLC 1.55

abrdn Life Sciences Investors 1.49

Partner Fund Management LP 1.46

Dimensional Fund Advisors, Inc. 1.40

Geode Capital Management, LLC 1.05

Jacobs Levy Equity Management, Inc. 1.03

Two Sigma Investments LLC 1.00

Aberdeen Group PLC 0.96

Vanguard Institutional Extnd Mkt Idx Tr 0.95

Bank of America Corp 0.87

Goldman Sachs Group Inc 0.85

Pale Fire Capital SE 0.83

FMR Inc 0.78

Maverick Capital Ltd 0.70

AQR Capital Management LLC 0.69

Royal Bank of Canada 0.64

Fidelity Extended Market Index 0.52

Schwab US Small-Cap ETF™ 0.43

DFA US Targeted Value I 0.42

Dimensional US Targeted Value ETF 0.33

Bruce 0.27

AXS Green Alpha ETF 0.23

Goldman Sachs Small Cp Val Insghts Instl 0.21

Extended Equity Market Fund K 0.19

Fidelity Total Market Index 0.16

Bridgeway Ultra-Small Company Market 0.14

Multi-Manager Small Cap Eq Strat Inst 0.14

Galileo - Biotech Innovation Fund S USD 0.14

Fidelity Series Total Market Index 0.13

Dimensional US Core Equity 2 ETF 0.12

Spartan Extended Market Index Pool F 0.11

Market Status

Strong Buy: 5

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 164.50 M

PB Ratio 1.2784

PE Ratio 0.0

Enterprise Value 59.53 M

Total Assets 313.31 M

Volume 808232

Company Financials

Annual Revenue FY23:34611000 34.6M, FY22:13851000 13.9M, FY21:9598000 9.6M, FY20:12361000 12.4M, FY19:5788000 5.8M

Annual Profit FY23:null 0.0M, FY22:13851000 13.9M, FY21:9598000 9.6M, FY20:12361000 12.4M, FY19:5788000 5.8M

Annual Net worth FY23:-94554000 -94.6M, FY22:-99421000 -99.4M, FY21:-66923000 -66.9M, FY20:-34308000 -34.3M, FY19:-23431000 -23.4M

Quarterly Revenue Q3/2025:2198000 2.2M, Q2/2025:2667000 2.7M, Q1/2025:2353000 2.4M, Q3/2024:2024000 2.0M, Q2/2024:3464000 3.5M

Quarterly Profit Q3/2025:1567000 1.6M, Q2/2025:2667000 2.7M, Q1/2025:2353000 2.4M, Q3/2024:2024000 2.0M, Q2/2024:2608000 2.6M

Quarterly Net worth Q3/2025:-27548000 -27.5M, Q2/2025:-54098000 -54.1M, Q1/2025:-39991000 -40.0M, Q3/2024:-34684000 -34.7M, Q2/2024:-37697000 -37.7M

Fund house & investment objective

Company Information Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Organisation Biotechnology

Employees 147

Industry Biotechnology

CEO Dr. Rachel E. Haurwitz Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow